BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 37658770)

  • 21. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21.
    Mortoglou M; Miralles F; Mould RR; Sengupta D; Uysal-Onganer P
    Eur J Cell Biol; 2023 Jun; 102(2):151318. PubMed ID: 37105116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-664 targets paired box protein 6 to inhibit the oncogenicity of pancreatic ductal adenocarcinoma.
    Wang Q; Wang J; Niu S; Wang S; Liu Y; Wang X
    Int J Oncol; 2019 May; 54(5):1884-1896. PubMed ID: 30896829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Girdin interaction with vimentin induces EMT and promotes the growth and metastasis of pancreatic ductal adenocarcinoma.
    Wang W; Chen H; Gao W; Wang S; Wu K; Lu C; Luo X; Li L; Yu C
    Oncol Rep; 2020 Aug; 44(2):637-649. PubMed ID: 32467989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance.
    Chen H; Zhu X; Sun R; Ma P; Zhang E; Wang Z; Fan Y; Zhou G; Mao R
    Invest New Drugs; 2020 Dec; 38(6):1707-1716. PubMed ID: 32468271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
    Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
    PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FUS-induced circRHOBTB3 facilitates cell proliferation via miR-600/NACC1 mediated autophagy response in pancreatic ductal adenocarcinoma.
    Yang T; Shen P; Chen Q; Wu P; Yuan H; Ge W; Meng L; Huang X; Fu Y; Zhang Y; Hu W; Miao Y; Lu Z; Jiang K
    J Exp Clin Cancer Res; 2021 Aug; 40(1):261. PubMed ID: 34416910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4.
    Fu Y; Liu X; Chen Q; Liu T; Lu C; Yu J; Miao Y; Wei J
    J Exp Clin Cancer Res; 2018 Jul; 37(1):130. PubMed ID: 29970191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of DIXDC1 correlates with enhanced cell growth and poor prognosis in human pancreatic ductal adenocarcinoma.
    Li X; Xiao Y; Fan S; Xiao M; Wang X; Zhu X; Chen X; Li C; Zong G; Zhou G; Wan C
    Hum Pathol; 2016 Nov; 57():182-192. PubMed ID: 27498060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Candidate agents for pancreatic ductal adenocarcinoma identified by a sub-pathway based method.
    Lin Y; Jin Y; Lin LJ; Cao Y; Zhang Y; Chen SF; Zheng CQ
    Gene; 2014 May; 540(2):232-7. PubMed ID: 24561286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer.
    Sasaki K; Takano S; Tomizawa S; Miyahara Y; Furukawa K; Takayashiki T; Kuboki S; Takada M; Ohtsuka M
    J Exp Clin Cancer Res; 2021 Jun; 40(1):212. PubMed ID: 34167573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
    Panzeri V; Manni I; Capone A; Naro C; Sacconi A; Di Agostino S; de Latouliere L; Montori A; Pilozzi E; Piaggio G; Capurso G; Sette C
    Mol Oncol; 2021 Feb; 15(2):579-595. PubMed ID: 33159833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
    Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.
    Wan C; Gong C; Ji L; Liu X; Wang Y; Wang L; Shao M; Yang L; Fan S; Xiao Y; Wang X; Li M; Zhou G; Zhang Y
    Mol Cell Biochem; 2015 Dec; 410(1-2):25-35. PubMed ID: 26276310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance.
    Meng Q; Liang C; Hua J; Zhang B; Liu J; Zhang Y; Wei M; Yu X; Xu J; Shi S
    Theranostics; 2020; 10(9):3967-3979. PubMed ID: 32226532
    [No Abstract]   [Full Text] [Related]  

  • 38. MicroRNA profiles following telmisartan treatment in pancreatic ductal adenocarcinoma cells.
    Yamana Y; Fujihara S; Kobara H; Oura K; Samukawa E; Chiyo T; Okamura M; Yamana H; Tadokoro T; Fujita K; Morishita A; Iwama H; Masaki T
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S305-S312. PubMed ID: 36510981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target.
    Kushibiki T; Nakamura T; Tsuda M; Tsuchikawa T; Hontani K; Inoko K; Takahashi M; Asano T; Okamura K; Murakami S; Kurashima Y; Ebihara Y; Noji T; Nakanishi Y; Tanaka K; Maishi N; Sasaki K; Park WR; Shichinohe T; Hida K; Tanaka S; Hirano S
    Mol Cancer Ther; 2020 Jan; 19(1):187-198. PubMed ID: 31597713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory IFIT3 renders chemotherapy resistance by regulating post-translational modification of VDAC2 in pancreatic cancer.
    Wang Z; Qin J; Zhao J; Li J; Li D; Popp M; Popp F; Alakus H; Kong B; Dong Q; Nelson PJ; Zhao Y; Bruns CJ
    Theranostics; 2020; 10(16):7178-7192. PubMed ID: 32641986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.